Industry-sponsored satellite symposia are educational, and some offer CME credit. This program is not a part of the official ACEP17 education program as planned by ACEP’s Educational Meetings Committee.
Explore This IssueACEP17 Monday Daily News
Management of Immune-Related Adverse Events in Patients Treated with Immune Oncology Agents: Role of Emergency Physicians in the Multidisciplinary Team
Monday, 6–8 a.m.
Registration, breakfast, and program
Marriott Marquis/Marquis Ballroom, Salon 3 and 4
Surgery, radiotherapy, and chemotherapy have been the main weapons against cancer for more than 50 years. Recently, immunotherapy has emerged as a novel way of fighting cancer. In the tumor microenvironment, immunosuppressive molecules such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein (PD-1) and its ligand, PD-L1, help the tumor evade immune attack. A class ofnovel immune oncology agents block these immune checkpoints,thereby reactivating cytotoxic T cells to destroy tumor cells. Several immunotherapeutic agents are now approved by the Food and Drug Administration, with several more in clinical trials. With these agents has emerged a new spectrum of dysimmune toxicity due to immune checkpoint blockade. Management of these immunotherapy-related adverse events (IRAEs) requires close collaboration among specialties. Join our cancer expert Arjun Balar, MD, as he reviews the evolving landscape of cancer immunotherapy and consequent management of IRAEs. Clinical trial–derived efficacy and safety data will be discussed, with attention given to adverse events, their identification, and management strategies. This learning opportunity features case-based presentation with a Q&A session that encourages attendees to maximize their learning and explore this evolving area of cancer treatment.
Grantor: Bristol-Myers Squibb
Strike Back Against Snakebite: Current Strategies and New Evidence in the Management of North American Pit Viper Envenomation
Monday, 6–9 p.m.
Registration, dinner, and program
Marriott Marquis/Marquis Ballroom, Salon 4
Approximately 5,000 to 9,000 people annually seek emergency care in theUnited States for crotaline snakebites, including rattlesnake, cottonmouth, and copperhead envenomation. The mainstay of care for North American pit viper envenomation is Fab antivenom. Join experts Charles Gerardo, MD, chief of emergency medicine at Duke University in Durham, North Carolina, and Eric Lavonas, MD, director of the Denver Health Emergency Department, for a comprehensive review of the best practices in medical management of crotaline envenomation in the United States. In addition, recently published data from a randomized controlled trial in copperhead envenomation willbe shared with the aim of providing evidence of the benefit of antivenom therapy in limb recovery following envenomation.
Grantor: BTG International Inc.